<DOC>
	<DOCNO>NCT02972268</DOCNO>
	<brief_summary>Clinical Trial Compare Efficacy Safety Solifenacin/Tamsulosin Combination Therapy Tamsulosin Monotherapy Lower Urinary Tract Symptoms due Benign Prostatic Hyperplasia</brief_summary>
	<brief_title>Clinical Trial Compare Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy LUTS Due BPH</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Over 45 year Benign Prostate Hyperplasia diagnose 20 mL &lt; TRUS Lower urinary tract symptom suggestive benign prostate hyperplasia , spontaneously agree join sign consent form Subjects history lower urinary tract cancer , include prostate cancer bladder cancer within past 3 year Subjects acute urinary retention within 12 week screen Subjects clinically significant severe cardiovascular disease ( unstable angina , myocardial infarction arrhythmia ) within 24 week screen Subjects hypersensitivity investigational product Subjects suspect confirm neurogenic bladder , bladder neck structure , bladder diverticulum Subjects myasthenia gravis , narrow angle glaucoma Subjects hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption SBP &gt; 180 mmHg DBP &gt; 100 mmHg HbA1c &gt; 9.0 % Subjects judge investigator unsuitable participate clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>